European Psychiatry - Volume 41 - April 2017

276 / 916

S272 25th European Congress of Psychiatry / European Psychiatry 41S (2017) S238–S302
Methods Retrospective naturalistic 2 years follow-up study of
FEP patients aged 18 to 35 admitted into the department of psy-
chiatry of the Beatriz Angelo’s hospital from 2012 to 2014. Data
on socio-demographics, clinical characteristics, appointments and
medication adherence and readmissions were collected.
Results Between 2012 and 2014 were admitted 56 patients with
a FEP into the department of psychiatry of the Beatriz Angelo’s hos-
pital. The greatmajority of the patients (67.9%) disengaged fromthe
treatment, both appointments and medication. Of those, 13.2% did
not attend any appointment, 26.3% attended between one and three
appointments and 60.5% attended at least 3 appointments before
disengaged. About 23%were readmitted between the 2 years follow
up period, 15.4% were readmitted more than once.
Conclusions The evidence reviewed indicates that approximately
30% of individuals with FEP disengage from services. Continuity of
care is of particular importancewith FEP, given evidence suggesting
that long-term care can improve symptoms and functioning and
reduces relapse risk.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW0487
Economic aspects in the treatment of
schizophrenia in Italy: Cost
consequences of an early long-acting
injectable anti-psychotics (lais)
approach
A. Marcellusi ∗, F.S. Mennini , R. Brugnoli , C. Rapinesi ,
G.D. Kotzalidis , S. De Filippis , D. Carrus , A. Ballerini ,
A. Francomano , G. Ducci , A. Del Casale , P. Girardi
1 Universita degli studi Tor Vergata, Ceis EEHTA, Roma, Italy
2 Consiglio Nazionale delle Ricerche CNR, Istituto di Ricerche sulla
Popolazione e le Politiche Sociali IRPPS, Roma, Italy
3 Universita La Sapienza, NESMOS Department Neurosciences,
Mental Health, and Sensory Organs, Roma, Italy
4 Clinic and Hospital, Villa von Siebenthal Neuropsychiatric, Roma,
Italy
5 ASL, VT, Viterbo, Italy
6 University of Florence, Department of Neuroscience, Psychology,
Drug Research and Child Health, Firenze, Italy
7 University of Palermo, Department of Experimental Biomedicine
and Clinical Neuroscience, Palermo, Italy
8 DSMASL, Roma1, Roma, Italy
9 Fondazione P. Alberto Mileno Onlus, Department of Psychiatric
Rehabilitation, Vasto, Italy
∗ Corresponding author.
Purpose The aim of this analysis was to evaluate the economic
consequences of a new treatment approach in the treatment of
schizophrenia in the Italian setting. In terms of direct costs, in Italy
was estimated that the main driver were represented by hospital-
ization and residential cost (71% of total direct cost per patient),
followed by semi-residential services (13%), anti-psychotic and
other drugs (8%) and ambulatory services (8).
Methods A probabilistic cost consequence model was developed
to estimate the potential cost reductions derived from an early
treatment with atypical long-acting injectable anti-psychotics
(aLAIs) drugs. A systematic literature review was carried out to
identify direct and indirect costs associated to the management of
schizophrenic patients in Italy. The model projects a scenario anal-
ysis in order to estimate potential cost reductions applying a new
model management (MoMa) based on patient recovery and early
aLAIs treatment.
Results Overall, the total economic burden associated with
schizophrenia was estimated at D2.7 billion per year. A total of
50.5% of the economic burden was related to indirect costs and
49.5% to direct costs. Drug costs correspond to 10% of the total
expenditure in terms of direct costs, while hospitalization and res-
idential costs accounts for 81%. Scenario analysis demonstrate a
potential cost reduction between 200million and 300million based
on the effects of MoMa over the reduction of hospitalization and
residential costs.
Conclusions This analysis was the first attempt to translate clin-
ical management aspects in economic consequences and will be a
useful instruments for decision maker.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW0488
Insight and social cognition in first
episode of psychosis
L. Martínez ∗, A. Mané , R. Cortizo , I. Cáceres , D. Treen ,
L. Galindo , P. Salgado , D. Berge
Hospital del Mar Medical Research Institute IMIM, Psychiatry,
Barcelona, Spain
∗ Corresponding author.
Introduction Impairment of insight in psychotic disorder is asso-
ciated with adverse impact in treatment compliance, outcome and
social functioning although its underlying mechanisms are still
unknown. Social cognition and more specifically Theory of mind
have been proposed to be correlated to insight. However, the rela-
tionship between both factors is still not well defined.
Aims To study the association between social cognition and
insight into mental illness in individuals with early psychosis
included in the first episode of psychosis program of Hospital del
Mar.
Methods From the 94 patients included in the first psychotic
episode program between January 2011 and January 2016, thirty-
eight patients were evaluated six months after the episode. The
three initial items of SUMD (Scale Unawareness of Mental Disorder)
were used to measure insight and MSCEIT (Mayer-Salovey-Caruso
Emotional Intelligence Test) was used to assess social cognition.
Linear correlation analysis by Pearson correlation was conducted.
Results Insight results of SUMD six months after the first episode
of psychosis were significantly associated with several subsections
of MSCEIT, such as experiential area total punctuation (r = –0.574;
P = 0.025), emotional facilitation section (r = –0.633; P = 0.011) and
the facial emotion perception task (r = –0.572; P = 0.026).
Conclusions Results suggest an association between insight and
emotional perception and facilitation performance in first episode
patients, which may suggest a role of social cognition in psychosis
insight impairment. Further research to better define the partic-
ipation of social cognition in insight into psychosis alteration is
mandatory to understand the etiology of insight, define treatment
targets and consequently improve the disorder prognosis.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW0489
Results of using micronutrients as
adjunctive treatment for psychotic
disorders
L. Mehl-Madrona ∗ ainguy
1 Eastern Maine Medical Center, Family Medicine Residency, Bangor,
USA
2 Coyote Institute, Education, Orono, USA
∗ Corresponding author.
Objective To evaluate the use of micronutrients (minerals and
vitamins) as adjunctive therapies for psychosis when added to con-
ventional medications.